Press Releases Keyword Search News Category Financial Year None20212020201920182017201620152014 Date Title 12/13/21 MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of ALS 12/10/21 MediciNova Announces MN-166 (ibudilast) Poster Presentation at the 32nd International Symposium on ALS/MND 11/22/21 MediciNova Announces New Data regarding MN-166 (ibudilast) in Glioblastoma Presented at the 26th Annual Meeting of the Society for Neuro-Oncology 11/11/21 MediciNova Announces MN-001 (tipelukast) Data regarding Lipid Metabolism in NASH/NAFLD to be Presented at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases 11/10/21 MediciNova Announces New Data regarding MN-166 (ibudilast) in Uveal Melanoma Presented at the CURE OM Global Science Meeting 11/03/21 MediciNova Announces New Data regarding MN-166 (ibudilast) in Glioblastoma to be Presented at the Annual Meeting of the Society for Neuro-Oncology 10/21/21 MediciNova Announces Abstract regarding the Mechanism by which MN-001 (tipelukast) Alters Triglyceride Metabolism Accepted for Presentation at the 19th International Symposium on Atherosclerosis (ISA2021) 09/02/21 MediciNova to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference 09/01/21 MediciNova Announces MN-001 (tipelukast) Abstract regarding Lipid Metabolism in NASH/NAFLD Accepted for Presentation at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases 08/30/21 MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 32nd International Symposium on ALS/MND 08/12/21 MediciNova Reports Second Quarter 2021 Financial Results and Business Update 07/06/21 MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Ophthalmic Disease 06/29/21 MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference 06/28/21 MediciNova to Conduct Mouse Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury 06/21/21 MediciNova Announces Positive Results from Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Nature’s Translational Psychiatry Journal 06/14/21 MediciNova to Participate in Maxim Group LLC Fireside Chat 06/07/21 MediciNova Initiates Sheep Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury 05/13/21 MediciNova Reports First Quarter 2021 Financial Results and Business Update 05/05/21 MediciNova Receives a Notice of Intention to Grant for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Europe 04/22/21 MediciNova Receives Gene Therapy Milestone Payments 04/19/21 MediciNova to Participate in the B. Riley Neuroscience Conference 04/15/21 MediciNova to Participate in the UBS Global Healthcare Virtual Conference 03/09/21 MediciNova Announces Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury 03/08/21 MediciNova to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference 03/03/21 MediciNova Announces Update on SARS-CoV-2 Vaccine for COVID-19 01/31/21 MediciNova Announces Closing of US$20 Million Private Placement Transaction 01/18/21 MediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Japan 01/11/21 MediciNova Enters into US$20 Million Securities Purchase Agreement with a fund managed by 3D Investment Partners
